Company research
iSpecimen Inc.
CIK 1558569Updated Sep 24, 2026
SecurityISPC · NASDAQ · equity
ISPC price & chart
Loading TradingView…
NASDAQ:ISPC on TradingView ↗About the company
iSpecimen is a technology-driven company founded to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells (“biospecimens”) for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.
In the news
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants ↗
Recent filings
DEF 14A filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
PRE 14A filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
8-K filing
Show 5 more recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement
Items 1.01, 1.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
424B4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,531,410Source | 9,350,230Source | 15,819,137Source | 24,617,653Source |
| Property, Plant and Equipment, NetUSD | 25,543Source | 93,563Source | 127,787Source | 225,852Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,880,835Source | 1,878,408Source | 2,343,666Source | 15,308,710Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 48,298Source | 1,444,636Source | 728,388Source | 1,597,915Source |
| Assets, CurrentUSD | 6,954,590Source | 3,587,936Source | 8,238,603Source | 19,675,721Source |
| Prepaid Expense and Other Assets, CurrentUSD | 25,457Source | 264,892Source | 292,079Source | 300,434Source |
| Operating Lease, Right-of-Use AssetUSD | 269,160Source | 327,977Source | 193,857Source | 184,692Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 6,443,179Source | 6,039,222Source | 6,078,060Source | 4,308,483Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 848Source | 170Source | 908Source | 892Source |
| Additional Paid in CapitalUSD | 85,437,703Source | 75,173,627Source | 69,104,313Source | 68,573,774Source |
| Retained Earnings (Accumulated Deficit)USD | -82,350,149Source | -71,862,617Source | -59,364,812Source | -48,265,324Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 840Source | — |
| Stockholders' Equity Attributable to ParentUSD | 3,088,231Source | 3,311,008Source | 9,741,077Source | 20,309,170Source |
| Liabilities and EquityUSD | 9,531,410Source | 9,350,230Source | 15,819,137Source | 24,617,653Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,231,306Source | 5,770,424Source | 6,048,930Source | 4,281,087Source |
| Operating Lease, Liability, CurrentUSD | 56,925Source | 43,369Source | 167,114Source | 158,451Source |
| Accounts Payable, CurrentUSD | 5,362,604Source | 4,197,561Source | 3,925,438Source | 2,459,063Source |
| Operating Lease, Liability, NoncurrentUSD | 211,873Source | 268,798Source | 29,130Source | 27,396Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 619,242Source | 1,168,786Source | 1,540,607Source | 1,531,238Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 5,005,598Source | — |
| Deferred Revenue, CurrentUSD | — | — | 415,771Source | 132,335Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 21,266Source | 249,675Source | 459,666Source | 678,613Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,336,475Source | 903,329Source | -564,488Source | -1,297,946Source |
| Increase (Decrease) in InventoriesUSD | -45,110Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 1,240,043Source | 272,123Source | 1,466,375Source | 1,626,385Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,240,608Source | -8,263,713Source | -5,807,550Source | -5,817,720Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,000,454Source | 1,979,554Source | -7,228,383Source | -3,191,190Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 454Source | 31,546Source | 19,478Source | 215,504Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,243,489Source | 5,818,901Source | 70,889Source | -3,421,359Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,880,835Source | 1,878,408Source | 2,343,666Source | 15,308,710Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,948Source | 33,751Source | 16,001Source | 161,579Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | — | — | — | 77,384Source |
| Amortization of Intangible AssetsUSD | 191,555Source | 191,555Source | 49,520Source | 1,182,766Source |
| Capitalized Computer Software, AmortizationUSD | 1,470,873Source | 2,036,981Source | 1,948,085Source | 1,182,766Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 5,005,598Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | 680Source | 0Source | — |
| DepreciationUSD | 68,474Source | 65,712Source | 117,543Source | 22,433Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -58Source | — | — |
| General and Administrative ExpenseUSD | 3,472,233Source | 6,067,276Source | 5,935,092Source | 6,932,727Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,949Source | 173,771Source | — | — |
| Inventory Write-downUSD | 6,000Source | — | — | — |
| Investment Income, InterestUSD | 3,748Source | — | — | — |
| LitigationSettlementLossUSD | 215,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -10,487,532Source | -12,497,805Source | -11,099,488Source | -10,245,922Source |
| Nonoperating Income (Expense)USD | -1,509,613Source | 230,240Source | 69,861Source | -59,840Source |
| Other Nonoperating Income (Expense)USD | -1,503,443Source | 406,181Source | -39,104Source | — |
| Proceeds from Issuance of Common StockUSD | 3,999,574Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 70,889Source | 78,641Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 9,928,184Source | 10,402,303Source |
| Cost of RevenueUSD | 1,904,888Source | 5,302,712Source | 4,820,268Source | 4,756,965Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -8,977,919Source | -12,728,045Source | -11,169,349Source | -10,186,082Source |
| Other Nonoperating Income (Expense)USD | -1,503,443Source | 406,181Source | -39,104Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -10,487,532Source | -12,497,805Source | -11,099,488Source | -10,245,922Source |
| Earnings Per Share, BasicUSD per share | -2.28Source | -17.58Source | -1.23Source | -1.16Source |
| Earnings Per Share, DilutedUSD per share | -2.28Source | -17.58Source | -1.23Source | -1.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,602,461Source | 710,852Source | 9,041,341Source | 8,844,307Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,602,461Source | 710,852Source | 9,041,341Source | 8,844,307Source |
| Interest Expense (non-operating)USD | 1,949Source | 173,771Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 191,555Source | 191,555Source | 49,520Source | 1,182,766Source |
| Capitalized Computer Software, AmortizationUSD | 1,470,873Source | 2,036,981Source | 1,948,085Source | 1,182,766Source |
| Costs and ExpensesUSD | 10,906,917Source | 22,019,160Source | 21,097,533Source | 20,588,385Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,730,902Source | 2,294,248Source | — | — |
| General and Administrative ExpenseUSD | 3,472,233Source | 6,067,276Source | 5,935,092Source | 6,932,727Source |
| Interest ExpenseUSD | — | — | 16,001Source | 238,963Source |
| Interest Income, OtherUSD | 3,748Source | 44,133Source | 339,750Source | 169,345Source |
| Investment Income, InterestUSD | 3,748Source | — | — | — |
| LitigationSettlementLossUSD | 215,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -1,509,613Source | 230,240Source | 69,861Source | -59,840Source |
| Other ExpensesUSD | 688,942Source | 1,493,310Source | — | — |
| Research and Development ExpenseUSD | — | 1,493,310Source | 1,618,833Source | 1,473,520Source |
| Selling and Marketing ExpenseUSD | 2,295,501Source | 4,945,269Source | 3,955,974Source | 3,445,344Source |
Offerings
Registration 333-297001
- Gross proceeds
- 4999998.9
- Net proceeds
- 4799998.94
- Deal price
- 1.3
- Shares
- 3846153
- Offering price
- $1.30
- Ticker
- ISPC
Registration 333-289725
Registration 333-286958
- Net proceeds
- 0.6719
- Deal price
- 0.7
- Ticker
- ISPC
Filing attachments
ea030100601ex4-1.htm · 8-K · 2026-08-07
EX-4.1 2 ea030100601ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT iSpecimen Inc. Warrant Shares: _______ Initial Exercise Date: ______, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (th…
Read attachment ↗ea030100601ex99-1.htm · 8-K · 2026-08-07
EX-99.1 5 ea030100601ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, ANNOUNCING THE PRICING OF THE OFFERING Exhibit 99.1 iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced tod…
Read attachment ↗ea030100601ex99-2.htm · 8-K · 2026-08-07
EX-99.2 6 ea030100601ex99-2.htm PRESS RELEASE DATED AUGUST 7, 2026, ANNOUNCING THE CLOSING OF THE OFFERING Exhibit 99.2 iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced tod…
Read attachment ↗ea029014301ex4-1.htm · 8-K · 2026-05-13
EX-4.1 2 ea029014301ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 iSPECIMEN INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER …
Read attachment ↗ea029014301ex99-1.htm · 8-K · 2026-05-13
EX-99.1 6 ea029014301ex99-1.htm PRESS RELEASE DATED MAY 8, 2026 Exhibit 99.1 iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accred…
Read attachment ↗ea028825801ex99-1.htm · 8-K · 2026-05-01
EX-99.1 4 ea028825801ex99-1.htm PRESS RELEASE DATED APRIL 24, 2026 Exhibit 99.1 iSpecimen Announces 1-for-40 Reverse Stock Split WOBURN, Mass., April 24, 2026 - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0…
Read attachment ↗